E. Gargaun et al.
P.335Phenotypic and genomic characterization as predictors of DMD 45 to 55 multi-exon skipping therapy
Neuromuscular Disorders 2019, vol. 29
doi: 10.1016/j.nmd.2019.06.449
![Logo France Génomique](https://www.france-genomique.org/wp-content/uploads/2019/03/logo-FG-blue-RVB-medium.png)
E. Gargaun et al.
P.335Phenotypic and genomic characterization as predictors of DMD 45 to 55 multi-exon skipping therapy
Neuromuscular Disorders 2019, vol. 29
doi: 10.1016/j.nmd.2019.06.449